Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Immunotherapy: New Developments and Challenges
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Immunotherapy: New Developments and Challenges

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 2452

Special Issue Editors

Dr. Xingxing Fan

E-Mail Website
Guest Editor
Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Macao, China
Interests: molecular pharmacology; cancer immunotherapy
Special Issues, Collections and Topics in MDPI journals
Dr. Paolo Coghi

E-Mail Website
Guest Editor
School of Pharmacy, Macau University of Science and Technology, Macau 999078, China
Interests: infectious disease; malaria; virus; cancer; medicinal chemistry; natural compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immunotherapy is a promising strategy for cancer treatment that harnesses the power of the immune system to fight tumor cells. However, current immunotherapeutic agents have limitations such as high toxicity, low specificity, and poor bioavailability.

The most successful cancer therapies are immune checkpoint inhibitors (ICIs), bi-specific T-cell engagers (BiTEs), and chimeric antigen receptor T cells (CAR-T cells). The possibility for a combination therapy built on the aforementioned techniques has recently been considered by researchers and has been demonstrated to have a significantly stronger impact on cancer therapy. Therefore, new research methodologies are necessary for a full explanation of the processes behind various cancer therapeutic approaches.

This Special Issue aims to publish original research papers, systematic reviews, and opinion pieces that focus on clinical/translational cancer immunotherapy, covering both in vitro and in vivo experiments on new immunotherapeutic strategies, therapy-related immune regulation, and immunotherapy markers.

Dr. Xingxing Fan
Dr. Paolo Coghi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment
  • small molecules
  • IDO1 inhibition
  • checkpoint inhibitor therapy
  • adoptive T cell therapy
  • metabolic reprogram
  • resistance mechanisms
  • immune modulation
  • immune reconstitution
  • combination therapy
  • immunosuppression

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 13605 KiB  
Article
The Transcriptional Landscape of Immune-Response 3′-UTR Alternative Polyadenylation in Melanoma
by Xiao Yang, Yingyi Wu, Xingyu Chen, Jiayue Qiu and Chen Huang
Int. J. Mol. Sci. 2024, 25(5), 3041; https://doi.org/10.3390/ijms25053041 - 6 Mar 2024
Viewed by 1795
Abstract
The prognosis of patients with malignant melanoma has been improved in recent decades due to advancements in immunotherapy. However, a considerable proportion of patients are refractory to treatment, particularly at advanced stages. This underscores the necessity of developing a new strategy to improve [...] Read more.
The prognosis of patients with malignant melanoma has been improved in recent decades due to advancements in immunotherapy. However, a considerable proportion of patients are refractory to treatment, particularly at advanced stages. This underscores the necessity of developing a new strategy to improve it. Alternative polyadenylation (APA), as a marker of crucial posttranscriptional regulation, has emerged as a major new type of epigenetic marker involved in tumorigenesis. However, the potential roles of APA in shaping the tumor microenvironment (TME) are largely unexplored. Herein, we collected two cohorts comprising melanoma patients who received immune checkpoint inhibitor (ICI) immunotherapy to quantify transcriptome-wide discrepancies in APA. We observed a global change in 3′-UTRs between responders and non-responders, which might involve DNA damage response, angiogenesis, PI3K-AKT signaling pathways, etc. Ten putative master APA regulatory factors for those APA events were detected via a network analysis. Notably, we established an immune response-related APA scoring system (IRAPAss), which exhibited a great performance of predicting immunotherapy response in multiple cohorts. Furthermore, we examined the correlation of APA with TME at the single-cell level using four single-cell immune profiles of tumor-infiltrating lymphocytes (TILs), which revealed an overall discrepancy in 3′-UTR length across diverse T cell populations, probably contributing to immunoregulation in melanoma. In conclusion, our study provides a transcriptional landscape of APA implicated in immunoregulation, which might lay the foundation for developing a new strategy for improving immunotherapy response for melanoma patients by targeting APA. Full article
(This article belongs to the Special Issue Immunotherapy: New Developments and Challenges)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop